Abstract
Background The city of Melbourne, Australia experienced two waves of the COVID-19 epidemic peaking, the first in March and a more substantial wave in July 2020. During the second wave, a series of control measure were progressively introduced that initially slowed the growth of the epidemic then resulted in decreasing cases until there was no detectable local transmission.
Methods To determine the relative efficacy of the progressively introduced intervention measures, we modelled the second wave as a series of exponential growth and decay curves. We used a linear regression of the log of daily cases vs time, using a four-segment linear spline model corresponding to implementation of the three successive major public health measures. The primary model used all reported cases between 14 June and 15 September then compared the projection of the model with observed cases predict future case trajectory up until the 31 October to assess the use of exponential models in projecting the future course and planning future interventions. The main outcome measures were the exponential daily growth constants, analysis of residuals and estimates of the 95% confidence intervals for the expected case distributions, comparison of predicted daily cases.
Results The exponential growth/decay constants in the primary analysis were: 0.122 (s.e. 0.004), 0.035 (s.e. 0.005), -0.037 (s.e. 0.011), and -0.069 (s.e. 0.003) for the initial growth rate, Stage 3, stage 3 + compulsory masks and Stage 4, respectively. Extrapolation of the regression model from the 14 September to the 31 October matched the decline in observed cases over this period.
Conclusions The four-segment exponential model provided an excellent fit of the observed reported case data and predicted the day-to-day range of expected cases. The extrapolated regression accurately predicted the decline leading to epidemic control in Melbourne.
Competing Interest Statement
NS and MH provide guidance to the Victorian Government COVID-19 response and receive funding from the Victorian Government for the Optimise Study and COVID-19 modelling work. NS received funding from Johnson & Johnson in Jun-Sep 2020 to provide incidence projections for potential vaccine trial sites. BC serves on the Australian National COVID-19 Health Research Advisory Committee that provides guidance to the Australian Federal Government COVID-19 response.
Clinical Trial
This was a retrospective analysis of the impact of public health measures on the COVID-19 epidemic in Melbourne. Therefore there was no clinical trial registered
Funding Statement
This study received no external funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
n/a
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available publicly from sources cited in the MS. Specifically, from the Victorian Government site
https://www.dhhs.vic.gov.au/ncov-covid-cases-by-lga-source-csv
Abbreviations
- DHHS
- Victorian Department of Health and Human Services
- k
- instantaneous growth constant
- Reff
- Effective Reproduction Ratio
- s.e.
- standard error
- C.I.
- confidence interval
